
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …

AstraZeneca has launched a new app that helps prostate cancer patients to monitor their PSA levels. It is not the …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

